VIRAX BIOLABS GROUP LTD
VRAXNASDAQπ #5207 by market capUS Equity
$0.33βΌ $0.05 (β13.46%)
Market closed Β· at closeTrack VRAX
Get earnings, price moves & breaking news on Telegram
24hβΌ 13.5%
7dβΌ 46.7%
14dβΌ 59.6%
30dβΌ 73.3%
ytdβΌ 96.6%
1yβΌ 96.6%
π¦Market Cap
$440,484
Small Cap
πRevenue Growth (YoY)
96.4%
High Growth
πGross Margin
62.0%
High
π΅FCF Margin
β
βοΈP/S Ratio
38.9x
Expensive
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $0.33 β $0.34
- 52-Week Range
- $0.29 β $21.75
- Volume (shares)
- 240
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.3M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $12,423
- Last Q Revenue
- $12,423
- P/E Ratio
- β
- P/S Ratio
- 38.9x
- EPS (TTM)
- $-23.09
- Dividend Yield
- β
- Dilution (1yr)
- +108.7%
VIRAX BIOLABS GROUP LTD
VRAXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12Kβ² +96.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.9%βΌ β107.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$6Mβ² +3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$5MβΌ β5.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
398Kβ² +108.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ² +$3M YoY
About VIRAX BIOLABS GROUP LTD
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.